EPAS1 and nonpapillary renal cell carcinoma: In pre-clinical models, novel small interfering RNA (siRNA) against HIF-2α such as ARO-HIF2 were shown to decrease HIF-2α levels and tumor volume in ccRCC tumorgraft models [54].